Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

This was the stock's second consecutive day of losses.

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...